Products for Research Use Only

Trimetazidine

CAT: 0804-HY-B0968A-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-B0968A-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Trimetazidine is a selective long chain 3-ketoyl coenzyme A thiolase inhibitor with an IC50 of 75 nM, which can inhibit β-oxidation of free fatty acid (FFA) . Trimetazidine is an effective antianginal agent and a cytoprotective agent, has anti-oxidant, anti-inflammatory, antinociceptive and gastroprotective properties. Trimetazidine triggers autophagy. Trimetazidine is also a 3-hydroxyacyl-CoA dehydrogenase (HADHA) inhibitor[1][2][3][4].
CAS Number
5011-34-7
UNSPSC
12352005
Hazard Statement
H302, H314, H412
Target
Autophagy
Type
Reference compound
Related Pathways
Autophagy
Applications
Cancer-programmed cell death
Field of Research
Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/trimetazidine.html
Purity
99.84
Solubility
DMSO : 116.67 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
COC1=CC=C(CN2CCNCC2)C(OC)=C1OC
Molecular Formula
C14H22N2O3
Molecular Weight
266.34
Precautions
H302, H314, H412
References & Citations
[1]Shenghu He, et al. Protective effects of trimetazidine against vascular endothelial cell injury induced by oxidation. Journal of Geriatric Cardiology, December 2008 , Vol 5 No 4.|[2]Kantor PF, et al. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res. 2000 Mar 17;86 (5) :580-8.|[3]Jain S, et al. Trimetazidine exerts protection against increasing current electroshock seizure test in mice. Seizure. 2010 Jun;19 (5) :300-2.|[4]Chrusciel P, et al. Defining the role of trimetazidine in the treatment of cardiovascular disorders: some insights on its role in heart failure and peripheral artery disease. Drugs. 2014 Jun;74 (9) :971-80.|[5]Hossain F, et al.Inhibition of Fatty Acid Oxidation Modulates Immunosuppressive Functions of Myeloid-Derived Suppressor Cells and Enhances Cancer Therapies. Cancer Immunol Res. 2015 Nov;3 (11) :1236-47.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light, stored under nitrogen)
Scientific Category
Reference compound1
Clinical Information
Launched
Citation 01
ACS Appl Nano Mater. 2025 Jun 9;8 (24) .|Acta Pharmacol Sin. 2022 Oct;43 (10) :2550-2561.|Cell Rep. 2024 Aug 7;43 (8) :114591.|Front Biosci (Landmark Ed) . 2025 Jan 20;30 (1) :25565.|J Adv Res. 2025 Mar 17:S2090-1232 (25) 00186-9.|J Ethnopharmacol. 2026 Feb 28:357:120899.|J Pathol. 2026 Jan;268 (1) :99-112.|J Pharm Biomed Anal. 2021 Feb 20:195:113870.|Nat Metab. 2025 Jan;7 (1) :84-101.|Sci Adv. 2025 Aug 29;11 (35) :eadu6271.|Wiad Lek. 2025;78 (1) :35-44.|Adv Sci (Weinh) . 2025 May 14:e2416419.|Anatol J Cardiol. 2019 Nov;22 (5) :232-239.|bioRxiv. 2025 April 10.|Mol Cell. 2020 Oct 1;80 (1) :43-58.e7.

Popular Products